Figure 2.

Molecular landscape of solid tumor patients who received nivolumab. The top panel represents the maximum tumor volume changes during nivolumab treatment based on RECIST criteria. The upper middle panel depicts the treatment response group, best objective response, age, and sex. The second middle panel demonstrates tumor mutational burden (TMB) per megabase, followed by MSIseq status and MSIsensor score. The fourth middle panel represents major somatic mutations in mismatch repair, homologous recombination-associated pathways, and cancer census genes. The bottom panel exhibits mutational signature activities. MSI, microsatellite instability; PR, microsatellite instability; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease